It is still undecided. Supposedly, the '520 patent is what the FDA is waiting on. The next Orange Book posting is on Feb. 15th, a Friday and OPEX day. The last posting was announced around 2PM. It could get interesting, if that happens again.
There was talk the FDA needed the '520 to avoid a lawsuit. Some doctors on iHub seem to think with a change in a law last Oct. (expiring), that this would allow for NCE on Vascepa.
There is also the conspiculous absence since the Vascepa launch of GSK's Lovaza website, possibly related to it stating that L raises LDL's, whereas Vascepa lowers them. The shorts saying AMRN stopped the reporting of sales figures as of 1/11 is dopey, as the sales didn't start until after then.
The prescribing doctors have a problem in continuing to prescribe Lovaza, with big difference in LDL results. At a minmum, they would have to notify every patient they prescribed with L of the differences, so that if anyone had a heartattack or stroke, they could not be held liable.